(Press-News.org)
Nasal-administered naloxone is more cost-effective and could help reduce the number of opioid-related fatalities compared to the current publicly funded intermuscular version, a new study has found.
Since 2016, Canada's opioid crisis has worsened, with over 40,000 opioid-related deaths, or about 22 deaths per day. Most of these accidental deaths (88 per cent) occur in British Columbia, Alberta and Ontario.
An effective way to help prevent opioid-related deaths is through community pharmacy-based naloxone programs. Currently, intramuscular naloxone is publicly funded across Canada, but it can be stress-inducing and difficult for bystanders to administer naloxone through a syringe. Intranasal naloxone, used as a simple nasal spray, is only publicly funded in Ontario, Quebec and the Northwest Territories.
The study by University of Waterloo researchers found a research gap in identifying the cost-effectiveness of implementing intranasal naloxone distribution across Canada through public funding. Mathematical modelling conducted by Waterloo researchers confirmed that intranasal naloxone is cost-effective when distributed to all Canadians and could help save additional lives. Based on the model, 151 deaths will be prevented per 10,000 people.
"Think of an EpiPen," said Ashley Cid, a PhD candidate in Waterloo's School of Pharmacy, which offers North America's most innovative pharmacy curriculum by integrating biomedical and pharmacy science with clinical, behavioural and social sciences that emphasizes patient-focused care.
"Similarly, naloxone is effective, safe, easy to use and is a medication meant to save someone's life regardless of whether you take opioid medication for a prescription or not. Providing publicly funded intranasal naloxone kits can effectively manage and reduce opioid-related fatalities due to increased distribution."
Cid adds that naloxone is a harm-reduction measure and does not increase the risk of opioid use. She believes policymakers should consider publicly funding intranasal naloxone across Canada and increasing distribution as it would help to mitigate the immediate public health opioid crisis and save more lives, especially in provinces like Alberta and British Columbia, where high rates of deaths are occurring.
"Providing intranasal naloxone through community pharmacies would have an immediate impact and be a great solution to increase access to publicly funded naloxone kits," Cid said. "I hope someday naloxone will be kept in first aid kits in your car, purse or home for emergencies."
The study, An economic evaluation of community pharmacy dispensed naloxone in Canada, was recently published in the Canadian Pharmacists Journal.
END
About The Study: In this systematic review and meta-analysis that included 41 randomized clinical trials of cancer screening, incidence of late-stage cancer may be a suitable alternative end point to cancer-specific mortality for some cancer types, but is not suitable for others. These results have implications for clinical trials of multicancer screening tests.
Authors: Hilary A. Robbins, Ph.D., M.H.S., M.S.P.H., of the International Agency for Research on Cancer in Lyon, France, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2024.5814)
Editor’s ...
Strategies implemented by firms are too ambitious and wide-ranging, according to a specialist, with their poor design and structure preventing digital transformation success.
Firms seeking to harness new digital technologies, such as artificial intelligence, must approach this organizational change in an entirely new way to avoid contributing to the $2.3 trillion wasted on unsuccessful projects globally so far.
This is the message of digital transformation expert Brian Harkin, author of Evolving from Digital Transformation to Digital Acceleration Using The Galapagos Framework, which helps business leaders understand how their approach to digital change ...
Combining pelvic floor exercises with behavioral therapy could be more effective than current medical treatments at helping men with frequent urges to urinate, new research in men has found.
The initial results from the Bladder Emptying Disorder Therapy (BEST) Trial are presented today [Monday 8 April 2024] at the European Association of Urology Congress in Paris. They reveal that an app-based therapy leads to significant improvements in the lower urinary tract symptoms that many millions of men experience – hesitancy, straining, frequent urges to urinate and emptying the bladder effectively. Full results ...
The boreal forest, covering much of Canada and Alaska, and the treeless shrublands to the north of the forest region, may be among the worst impacted by climate change over the next 500 years, according to a new study.
The study, led by researchers at the White Rose universities of York and Leeds, as well as Oxford and Montreal, and ETH, Switzerland, ran a widely-used climate model with different atmospheric concentrations of carbon dioxide to assess the impact climate change could have on the ...
About The Study: In this randomized clinical trial including 103 American Indian patients, a telephone-based strategy of remote initiation and titration for outpatients with heart failure with reduced ejection fraction led to improved rates of guideline-directed medical therapy at 30 days compared with usual care. This low-cost strategy could be expanded to other rural settings where access to care is limited.
Authors: Lauren A. Eberly, M.D., M.P.H., of the Indian Health Service in Gallup, New Mexico, is the corresponding author.
To access the embargoed study: ...
ABSTRACTS: CT002, CT003
SAN DIEGO ― Researchers from The University of Texas MD Anderson Cancer Center presented encouraging findings today from two clinical trials in a plenary session highlighting advances in novel immunotherapy approaches at the American Association for Cancer Research (AACR) Annual Meeting 2024. The studies describe the use of chimeric antigen receptor (CAR) T cell therapy in patients with advanced kidney cancer and an oncolytic immunotherapy for patients with skin cancer following organ transplants. Information on all MD Anderson AACR Annual Meeting content can be found at MDAnderson.org/AACR.
Novel allogenic ...
New data presented today by Memorial Sloan Kettering Cancer Center (MSK) researchers show an experimental approach to treating pancreatic cancer with the messenger RNA (mRNA)-based therapeutic cancer vaccine candidate, autogene cevumeran, continues to show potential to stimulate an immune response that may reduce the risk of the disease returning after surgery. New results from a phase 1 clinical trial show that the cancer vaccine candidate activated immune cells that persisted in the body for up to three years after treatment in certain patients. In addition, a vaccine-induced immune ...
About The Study: Most cancer drugs granted accelerated approval did not demonstrate benefit in overall survival or quality of life within five years of accelerated approval. Patients should be clearly informed about the cancer drugs that use the accelerated approval pathway and do not end up showing benefits in patient-centered clinical outcomes.
Authors: Aaron S. Kesselheim, M.D., J.D., M.P.H., of Brigham and Women’s Hospital and Harvard Medical School in Boston, is the corresponding author.
To access the embargoed ...
KEY TAKEAWAYS
Researchers at Mass General Brigham tested a remote patient education and navigation program with 200 patients who had type 2 diabetes and elevated cardiovascular/kidney risk.
Patients who received education simultaneously with treatment were more likely to begin and adhere to treatment while a period of education prior to therapy initiation was inferior for prescription acceptance and therapy uptake.
The study highlights the importance of “striking while the iron is hot” and the potential for remote, team-based care to bridge ...
Sophia Antipolis, France – 7 April 2024: The first EU-wide trial aiming to improve the care of elderly atrial fibrillation patients with additional chronic health conditions has enrolled its first patient. The EU-funded EHRA-PATHS study is coordinated by the European Society of Cardiology (ESC) and the European Heart Rhythm Association (EHRA) of the ESC.
Atrial fibrillation is the most common heart rhythm disorder, affecting more than 40 million individuals worldwide.1 The likelihood of developing the condition increases with age and the number of other conditions such as high blood pressure, ...
